Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer

Lori Wirth, MD, associate professor, medicine, Harvard Medical School; medical director, Center for Head and Neck Cancers; Massachusetts General Hospital, discusses the significance of the June 2024 FDA full approval of selpercatinib (Retevmo) for adult and pediatric patients at least 2 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine (RAI) refractory, if RAI is appropriate.
Website: www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive